Bottom line
Is FEVAX a good fund? The bottom line
FEVAX is the Class A share class of First Eagle U.S. Fund, an actively managed large blend mutual fund from MFS.
Its expense ratio is 1.14% — about $114 a year on every $10,000 invested, more expensive than 71% of large blend funds we track.
It returned +16.5% over one year, +11.5% a year over five years, +10.3% a year over ten (as of Dec 31, 2025, per its prospectus).
With $1.6 billion in net assets and 86 holdings, its largest position is Gold bullion (10.5%) and the top 10 make up 36.5% of the portfolio.
This share class carries a front-end sales charge of up to 5%; a no-load class or ETF alternative can avoid it.
What to watch
- Expensive for its category (1.14%)
- Front-end sales load up to 5%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What FEVAX invests in
First Eagle U.S. Fund (U.S. Fund or the Fund) seeks long-term growth of capital by investing, under normal market conditions, at least 80% of its net assets (plus any borrowings for investment purposes) in domestic equity and debt securities.
To achieve its objective of long-term capital growth, the U.S. Fund will normally invest at least 80% of its net assets (plus any borrowings for investment purposes) in domestic equity (e.g., common stocks) and debt instruments (e.g., notes and bonds) and may invest to a lesser extent in securities of non-U.S. issuers (including American Depositary Receipts, Global Depositary Receipts and European Depositary Receipts). In particular, the Fund seeks companies exhibiting financial strength and stability, strong management and fundamental value. Investment decisions for the Fund are made without regard to the capitalization (size) of the companies in which it invests. The Fund may invest in any size company, including large, medium and smaller companies. The debt instruments in which the Fund may invest include fixed income securities without regard to credit rating or time to maturity…
From the fund's prospectus (filed May 21, 2026).
FEVAX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| FEVAX | +16.5% | +11.5% | +10.3% |
| Large Blend median | +13.8% | +9.7% | +10.9% |
Source: Fund prospectus, as of Dec 31, 2025
What FEVAX costs
On a $10,000 investment, FEVAX's 1.14% expense ratio costs about $114 a year. The prospectus estimates $1,817 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.
FEVAX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Gold bullion | 10.49% |
| 2 | Alphabet, Inc. | 4.01% |
| 3 | Becton Dickinson & Co. | 3.65% |
| 4 | Meta Platforms, Inc. | 3.07% |
| 5 | Bank of New York Mellon Corp. (The) | 3.02% |
| 6 | Elevance Health, Inc. | 2.83% |
| 7 | HCA Healthcare, Inc. | 2.66% |
| 8 | Philip Morris International, Inc. | 2.53% |
| 9 | Salesforce, Inc. | 2.11% |
| 10 | Oracle Corp. | 2.10% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 36.5% of the fund. See all top 25 holdings and asset mix →